Literature DB >> 25156972

Immunomodulators to treat recurrent miscarriage.

Jelmer R Prins1, Tom E C Kieffer2, Sicco A Scherjon2.   

Abstract

Recurrent miscarriage is a reproductive disorder affecting many couples. Although several factors are associated with recurrent miscarriage, in more than 50% of the cases the cause is unknown. Maladaptation of the maternal immune system is associated with recurrent miscarriage and could explain part of its pathophysiology. Modulating the maternal immune system toward pregnancy tolerance could benefit pregnancy outcome. Although there is a clear scientific rationale that modulating the maternal immune system could benefit recurrent miscarriage, only a few studies suggest possible beneficial effects of immune modulators as a therapy for recurrent miscarriage. Therapies skewing the maternal immune response to a tolerating regulatory T cell rich environment seem especially promising; however, more research is needed to find effective and safe maternal immune modulators for reproductive pathologies as recurrent miscarriage. Moreover, the possible side effects on maternal, fetal, and neonatal immune function are essentially unknown, and its elucidation is crucial before any possible therapeutic strategies could be clinically implemented.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Keywords:  Immune system; Recurrent miscarriage; Review; Therapy

Mesh:

Substances:

Year:  2014        PMID: 25156972     DOI: 10.1016/j.ejogrb.2014.07.038

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  2 in total

1.  Low-dose lymphocyte immunotherapy rebalances the peripheral blood Th1/Th2/Treg paradigm in patients with unexplained recurrent miscarriage.

Authors:  Mengyuan Liu; Xin Zhen; Hongyan Song; Junhao Chen; Xiaoling Sun; Xiaoqin Li; Jianjun Zhou; Guijun Yan; Lijun Ding; Haixiang Sun
Journal:  Reprod Biol Endocrinol       Date:  2017-12-16       Impact factor: 5.211

2.  Development of a core outcome set for immunomodulation in pregnancy (COSIMPREG): a protocol for a systematic review and Delphi study.

Authors:  Jelmer R Prins; Floor Holvast; Janneke van 't Hooft; Arend F Bos; Jan Willem Ganzevoort; Sicco A Scherjon; Sarah A Robertson; Sanne J Gordijn
Journal:  BMJ Open       Date:  2018-08-05       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.